Awesome man earning up 217% shorts always trying to paint some bleak picture when the opposite is the real fact here. Earnings just keep getting better and better and better every quarter. Going to surpass their $40 million estimate with ease.
No concern, in the company's best long-term interest. Operating loss increase in diagnostic/therapeutic segment is expected with ramp-up toward product launch, clinical trial work, and supporting hardware and software infrastructure.
News 
Market Data 
Discover 
